A Randomized, Double-Blinded Clinical Trial to Evaluate the Immunogenicity Using Additional Dose of Medium-dosage or High-dosage COVID-19 Vaccine (Vero Cell), Inactivated in Populations Who Have Completed Primary Immunization 5-9 Months
Latest Information Update: 18 Aug 2022
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Aluminium hydroxide
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Sinovac Biotech
Most Recent Events
- 09 Aug 2022 Status changed from active, no longer recruiting to completed.
- 16 Mar 2022 Planned primary completion date changed from 20 Feb 2022 to 20 Apr 2022.
- 30 Dec 2021 New trial record